

REMARKS

Claims 1 is currently amended by this response, and claim 5 is cancelled. Claims 1, 11-13, and 15 remain pending after entry of the present amendment. The Applicant reserves the right to pursue any cancelled subject matter in a Divisional or Continuation application.

Claim 1 is amended to address the Examiner's assertion that the claim should only be directed to nonheterocyclic and nonheteroaryl subject matter, and to fix a typographical error in the spelling of the word "substituents." Applicants also submit that the present amendments are believed to introduce no new matter, support for the amendments being found at the places indicated in the specification.

I. Restriction Requirement

The Examiner required that the subject matter of the claims be limited to nonheterocyclic and nonheteroaryl groups exclusively. To further the prosecution of the application, applicants have so limited the claims by the present amendment to the examined subject matter.. In view of the aforesaid, Applicants submit that the claims are directed to what the Examiner notes to be elected subject matter, and thus any issue regarding this point are rendered moot. Consequently, Applicants request the reconsideration and withdrawal of the Restriction issue.

II. Rejection of Claim 5 Pursuant to 35 USC §112, second paragraph

Claim 5 is rejected under 35 USC §112, second paragraph, as being indefinite for failing to point out and distinctly claim the subject matter which applicant regards as the invention. Claim 5 has been cancelled. In view of the aforesaid, Applicants submit that the rejection is rendered moot, and thus request the reconsideration and withdrawal of the rejection.

III. Conclusion

Applicants submit that in view of the aforesaid that the application is in condition for allowance and request action to that end.


The Commissioner is hereby authorized to charge the fee required and any additional fees that may be needed to Deposit Account No. 18-1982.

If any additional prosecution issue arise that could be furthered by a telephone discussion, the Examiner is invited to call the undersigned practitioner at the number provided below.

May 30, 2008

sanofi-aventis
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone: (908) 231-5674
e-mail: raymond.parker@sanofi-aventis.com

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Raymond S. Parker', is written over a horizontal line.

Raymond S. Parker, Reg. No. 34893
Attorney for Applicant